Quick Answer
Insight Molecular Diagnostics Inc. reported Cash And Cash Equivalents At Carrying Value of $11.58 million for the year ending 2025.
- Insight Molecular Diagnostics Inc. showed an increase of +34.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Insight Molecular Diagnostics Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Insight Molecular Diagnostics Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 11,368.3%.
- Historical annual values: Fiscal year 2025: $11.58 million | Fiscal year 2024: $8.64 million | Fiscal year 2023: $9.43 million | Fiscal year 2022: $19.99 million | Fiscal year 2021: $32.95 million | Fiscal year 2020: $7.14 million | Fiscal year 2019: $22.07 million | Fiscal year 2018: $8.03 million | Fiscal year 2017: $7.60 million | Fiscal year 2016: $10.17 million | Fiscal year 2015: $8.00 million | Fiscal year 2014: $257.0 thousand | Fiscal year 2013: $101.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: